Article Text

Download PDFPDF
Opsoclonus-myoclonus-ataxia syndrome associated with bacterial urinary tract infection
  1. Hasara Jayasekara1,
  2. Janitha Sampath Wickramarathne1,
  3. Damith Sanjaya Liyanage2 and
  4. Peduru Arachchige Jayasinghe2
  1. 1Postgraduate Institute of Medicine, University of Colombo, Colombo, Sri Lanka
  2. 2National Hospital, Karapitiya, Sri Lanka
  1. Correspondence to Dr Hasara Jayasekara; hasarajay{at}gmail.com

Abstract

Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare acquired neurological disorder characterized by opsoclonus, focal or diffuse myoclonus, truncal instability and associated other cerebellar signs and ataxia. While predominantly affecting children, it can rarely manifest in adults and could be associated with infections, paraneoplastic syndrome, drugs or other neurological disorders. We present a case of an elderly gentleman presenting with OMAS associated with a culture-positive urinary tract infection with Escherichia coli, successfully treated with antibiotics and immunoglobulins resulting in significant recovery.

  • Movement disorders (other than Parkinsons)
  • Urinary tract infections

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors The following authors were responsible for drafting the text, sourcing and editing the clinical investigations and critical revision for intellectual content: HJ, JSW, DSL and PAJ. The following authors gave the final approval for the manuscript: DSL and PAJ.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.